Map Pharmaceuticals, Inc

A New Direction in Medicine
Home | Site Map | Careers
 
  • About Us
    • Message from the CEO
    • Management Team
    • Board of Directors
    • Partnering
    • Careers
  • Product Portfolio
    • LEVADEX®
  • Science & Technology
    • Proven Drugs
    • Innovative Delivery
    • Targeted Dosing
    • Publications
  • Investors & News
    • IR Home
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Management
    • Board of Directors
    • Committee Composition
    • Annual Reports
    • SEC Filings
    • Stock Information
    • Analyst Coverage
    • Contact Us
    • Publications
  • Contact Us
 
  • Privacy Policy
  • Terms of Use
  • Site Map

Sitemap

About Us

  • Message from the CEO
  • Management Team
  • Board of Directors
  • Partnering
  • Careers
    • Open Positions
    • Our Values
    • Benefits
    • Community Relations

Product Portfolio

  • LEVADEX®
    • Disease

Science & Technology

  • Proven Drugs
  • Innovative Delivery
  • Targeted Dosing
  • Publications

Investors & News

  • IR Home
  • Press Releases
  • Events and Presentations
  • Corporate Governance
  • Management
  • Board of Directors
  • Committee Composition
  • Annual Reports
  • SEC Filings
  • Stock Information
  • Analyst Coverage
  • Contact Us
  • Publications

Contact Us

Privacy Policy

Terms of Use

Site Map

Recent News

  • February 7, 2013

    Allergan, Inc. and MAP Pharmaceuticals, Inc. Announce the Federal Trade Commission Has Granted Early Termination of Waiting Period Under Hart-Scott-Rodino Act

  • January 22, 2013

    Allergan, Inc. to Acquire MAP Pharmaceuticals, Inc.

  • January 2, 2013

    MAP Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference

Read More

 
  • © 2011 MAP Pharmaceuticals, Inc. All Rights Reserved.
  • Privacy Policy
  • Terms of Use
  • Site Map